For United Kingdom-based Mallinckrodt, the deal would bring a pair of currently marketed pharmaceutical products: Amitiza (lubiprostone), a medication for constipation, and Rescula (unoprostone isopropyl
ophthalmic solution 0.15%), a treatment for ocular hypertension and open-angle glaucoma.
Through the acquisition, Mallinckrodt adds a second commercial asset from Sucampo which is Rescula (unoprostone isopropyl
ophthalmic solution) 0.15%.
There are no human eye data for unoprostone isopropyl
(Rescula), a synthetic docosanoid.
The company also receives revenue from sales of Rescula (unoprostone isopropyl
) in Japan.
M2 PHARMA-March 9, 2015-Sucampo to return all licenses for intraocular pressure compound Unoprostone Isopropyl to R-Tech Ueno
According to Sucampo, the licenses granted the exclusive development and commercialisation rights to unoprostone isopropyl globally except for Japan, People's Republic of China, Taiwan and Korea and covered certain indications, including the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, retinitis pigmentosa and geographic atrophy.
, which is a member of its family of prostones and a synthetic docosanoid, may have a local effect on BK channels in the eye.
M2 EQUITYBITES-March 9, 2015-Sucampo to return all licenses for intraocular pressure compound Unoprostone Isopropyl
to R-Tech Ueno
RESCULA's (unoprostone isopropyl ophthalmic solution) approval was awarded by the US Food and Drug Administration (FDA).
Unoprostone isopropyl may have a local effect on BK (Big Potassium) channels in the eye.
Under the terms of this licence agreement, SMR holds exclusive rights to develop, use, make, have made, export, commercialise, promote, offer for sale and sell RESCULA (unoprostone isopropyl
) in Europe and the rest of world, as well as USA and Canada.